BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37470943)

  • 1. Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
    Li C; Yuan Q; Deng T; Xu G; Hou J; Zheng L; Wu G
    Breast Cancer; 2023 Nov; 30(6):965-975. PubMed ID: 37470943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
    Ergun Y; Ucar G; Akagunduz B
    Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis.
    Petrelli F; Rea C; Parati MC; Borgonovo K; Ghilardi M; Dottorini L; Luciani A; Ghidini M; Ruatta F; Garrone O; Tomasello G
    Anticancer Res; 2023 Oct; 43(10):4303-4313. PubMed ID: 37772569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.
    Molinelli C; Jacobs F; Agostinetto E; Nader-Marta G; Ceppi M; Bruzzone M; Blondeaux E; Schettini F; Prat A; Viale G; Del Mastro L; Lambertini M; de Azambuja E
    ESMO Open; 2023 Aug; 8(4):101592. PubMed ID: 37413762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
    Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
    BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis.
    Tang Y; Shen G; Xin Y; Li Z; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
    Ther Adv Med Oncol; 2023; 15():17588359231156669. PubMed ID: 36872948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival differences between HER2-0 and HER2-low-expressing breast cancer - A meta-analysis of early breast cancer patients.
    Yang C; Zhang X; Chen Y; Li P; Zhang J; Xu A; Huang N; Liang M; Chen Y; Wang K
    Crit Rev Oncol Hematol; 2023 May; 185():103962. PubMed ID: 36921780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis.
    Xia LY; Cao XC; Yu Y
    World J Surg Oncol; 2024 Apr; 22(1):106. PubMed ID: 38643188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis.
    Wei T; Wang D; Gao S; Wang X; Yue J; Kang Y; Ju J; Yang Z; Shuai Y; Yuan P
    Front Oncol; 2023; 13():1100332. PubMed ID: 36816954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
    Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
    BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
    Lohmann AE; Soldera SV; Pimentel I; Ribnikar D; Ennis M; Amir E; Goodwin PJ
    J Natl Cancer Inst; 2021 Nov; 113(11):1465-1475. PubMed ID: 33620467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
    Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
    Tan G; Chu C; Gui X; Li J; Chen Q
    Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Li JJ; Yu Y; Ge J
    Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
    Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
    Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
    Chen Z; Jia H; Zhang H; Chen L; Zhao P; Zhao J; Fu G; Xing X; Li Y; Wang C
    Breast Cancer Res Treat; 2023 Nov; 202(2):313-323. PubMed ID: 37639064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis.
    Xu H; Liu Z; Shi H; Wang C
    BMC Cancer; 2020 Nov; 20(1):1051. PubMed ID: 33131491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.